Brand Name | Status | Last Update |
---|---|---|
enhertu | Biologic Licensing Application | 2025-01-28 |
herceptin | Biologic Licensing Application | 2024-11-18 |
herceptin hylecta | Biologic Licensing Application | 2024-11-21 |
hercessi | Biologic Licensing Application | 2025-03-21 |
herzuma | Biologic Licensing Application | 2025-02-12 |
kadcyla | Biologic Licensing Application | 2024-11-18 |
kanjinti | Biologic Licensing Application | 2024-12-20 |
ogivri | Biologic Licensing Application | 2024-11-30 |
ontruzant | Biologic Licensing Application | 2025-03-11 |
ontruzant ontruzant | Biologic Licensing Application | 2024-03-01 |
Expiration | Code | ||
---|---|---|---|
trastuzumab, Herceptin, Genentech, Inc. | |||
2117-10-20 | Orphan excl. |
Code | Description |
---|---|
J9316 | Injection, pertuzumab, trastuzumab, and hyaluronidase-zzxf, per 10 mg |
J9354 | Injection, ado-trastuzumab emtansine, 1 mg |
J9355 | Injection, trastuzumab, excludes biosimilar, 10 mg |
J9356 | Injection, trastuzumab, 10 mg and hyaluronidase-oysk |
J9358 | Injection, fam-trastuzumab deruxtecan-nxki, 1 mg |
Q5112 | Injection, trastuzumab-dttb, biosimilar, (ontruzant), 10 mg |
Q5113 | Injection, trastuzumab-pkrb, biosimilar, (herzuma), 10 mg |
Q5114 | Injection, trastuzumab-dkst, biosimilar, (ogivri), 10 mg |
Q5116 | Injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg |
Q5117 | Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Breast neoplasms | D001943 | EFO_0003869 | C50 | 18 | 60 | 47 | 5 | 19 | 139 |
Stomach neoplasms | D013274 | EFO_0003897 | C16 | — | 9 | 4 | 1 | 3 | 16 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | 4 | 7 | 4 | — | 1 | 14 |
Inflammatory breast neoplasms | D058922 | — | — | 1 | 1 | 3 | — | — | 4 |
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | 3 | 1 | — | — | 3 |
Urinary bladder neoplasms | D001749 | — | C67 | — | 3 | 1 | — | — | 3 |
Cardiotoxicity | D066126 | EFO_1001482 | — | — | — | 1 | — | 1 | 2 |
Colorectal neoplasms | D015179 | — | — | — | 2 | 1 | — | — | 2 |
Mucinous adenocarcinoma | D002288 | — | — | — | 1 | 2 | — | — | 2 |
Ductal carcinoma breast | D018270 | — | — | — | 1 | 2 | — | — | 2 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | 2 | 1 | — | — | 2 |
Lung neoplasms | D008175 | — | C34.90 | — | 2 | 1 | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Adenocarcinoma | D000230 | — | — | — | 3 | — | — | — | 3 |
Non-small-cell lung carcinoma | D002289 | — | — | — | 3 | — | — | — | 3 |
Esophageal neoplasms | D004938 | — | C15 | 1 | 3 | — | — | — | 3 |
Triple negative breast neoplasms | D064726 | — | — | 1 | 1 | — | — | — | 2 |
Neoplasm metastasis | D009362 | EFO_0009708 | — | — | 2 | — | — | — | 2 |
Carcinoma | D002277 | — | C80.0 | 1 | 2 | — | — | — | 2 |
Urologic neoplasms | D014571 | — | C64-C68 | — | 2 | — | — | — | 2 |
Non-hodgkin lymphoma | D008228 | — | C85.9 | — | 1 | — | — | — | 1 |
Multiple myeloma | D009101 | — | C90.0 | — | 1 | — | — | — | 1 |
Unknown primary neoplasms | D009382 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
Head and neck neoplasms | D006258 | — | — | 1 | — | — | — | — | 1 |
Drug common name | Trastuzumab |
INN | trastuzumab |
Description | Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer. It is specifically used for cancer that is HER2 receptor positive. It may be used by itself or together with other chemotherapy medication. Trastuzumab is given by slow injection into a vein and injection just under the skin.
|
Classification | Antibody |
Drug class | monoclonal antibodies |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | >5U6A:A|Light Chain
DIQMTQSPILLSASVGDRVTITCRASQDVNTAVAWYQQRTNGSPRLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQP
EDEADYYCQQHYTTPPTFGAGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ
ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
>5U6A:B|Heavy Chain
EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQSPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAY
LQMNSLRAEDTAIYYCSRWGGDGFYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS
WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC |